HOME >> BIOLOGY >> NEWS
Scientists take next step in understanding potential target for ovarian cancer treatment

A traffic cop protein in the cell may have an even more important role: transporting a messenger protein that tells components in the nucleus to stop cell growth. The discovery of this additional role may lead to diagnostic tools and earlier treatments for ovarian cancer.

A Penn State College of Medicine research team, led by Kathleen M. Mulder, Ph.D., professor of pharmacology, is studying the normal function of a protein called km23, the traffice cop protein, because the team previously found altered forms of the protein in 42 percent of tumor tissue samples taken from women with ovarian cancer.

No similar alterations were found in normal human tissues, suggesting that the km23 alterations may be a possible diagnostic indicator for development of ovarian cancer and that the km23 protein itself may be a possible target for cancer therapies.

km23 is part of the signaling system for a growth factor called TGF, which attaches to TGF receptors at the cell membrane. It activates km23 into action.

km23 acts like a traffic cop for specific proteins as they move in the cell on a highway called a microtubule. It is responsible for helping to match the right cellular cargo with the right motor complex to get the cargo to the correct destination when its needed. One of those precious cargoes is a TGF-signaling component that must get to the cell nucleus to turn on specific genes that help stop cell growth.

Alterations in the TGF signaling system are known to contribute to cancer, Mulder said. We have been searching for new components of this signaling system to determine whether they are also altered in cancer and contribute to its development. These components can then be used to design new treatment strategies for cancer once we understand how they normally function.

In the current study, Mulders team found that blocking km23 from doing its job in the TGF- signaling system disrupted the transport of the sig
'"/>

Contact: Megan Manlove
mmanlove@hmc.psu.edu
717-531-8606
Penn State
16-Jul-2007


Page: 1 2

Related biology news :

1. Scientists show that mitochondrial DNA variants are linked to risk factors for type 2 diabetes
2. Scientists prove that disputed Korean stem cell line comes from an unfertilized egg and not cloning
3. Scientists move closer to bio-engineered bladders
4. Scientists find stem cell switch
5. Scientists discover new way to study nanostructures
6. Scientists a step closer to understanding how anaesthetics work in the brain
7. Scientists to make news at Computational Biology Conference
8. Accident-prone? Scientists link brain function to knee injuries
9. Scientists find brown fat master switch
10. Scientists identify 2 distinct Parkinsons networks
11. Scientists follow familiar TRAIL to new cancer therapy

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:9/3/2020)... (PRWEB) , ... September 03, 2020 , ... ... world data, today announced that an extensive third-party assessment of the company’s security ... compliant when measured against federal security regulations. The comprehensive evaluation reviewed Litmus’ processes ...
(Date:8/26/2020)... ... August 25, 2020 , ... ... developing novel pharmaceuticals targeting mitochondria, in partnership with Essex Bio-Technology, a bio-pharmaceutical ... pivotal U.S. Phase 3 VISTA-2 study of SkQ1 ophthalmic solution in patients ...
(Date:8/26/2020)... ... 2020 , ... Modality Solutions, a biopharmaceutical cold chain validation engineering ... The list is the most prestigious ranking of the nation’s fastest-growing private companies. Modality ... list, reported three-year revenue growth of 71 percent. , The Inc. 5000 list ...
Breaking Biology News(10 mins):
(Date:8/12/2020)... ... 2020 , ... The FSHD Society announced today that it ... Trial Research Network (FSHD CTRN), with consideration of follow-on funding of $300,000 ... research centers in the United States and Europe with expertise in FSHD clinical ...
(Date:8/3/2020)... , ... August 03, 2020 , ... Introducing Ardent Animal ... transformative growth, , Known as MediVet Biologics since its formation ... The new Ardent Animal Health will build on its base of innovative ...
(Date:7/31/2020)... ... July 29, 2020 , ... ... the leading global provider of advanced delivery technologies, development, and manufacturing solutions for ... they have entered into a strategic partnership whereby Catalent will provide support for ...
(Date:7/18/2020)... ... ... After research model surgery and catheter implantation, the long journey of catheter maintenance and ... successful study, while protecting and accessing the catheter or device post-surgery is often undervalued ... Envigo in a live webinar on Wednesday, August 5, 2020 at ...
Breaking Biology Technology:
Cached News: